Basiliximab in lung transplantation: preliminary experience

Area of Science:

• Immunology
• Transplantation Medicine
• Pharmacology

Background:

• Basiliximab, an anti-interleukin-2 monoclonal antibody, is established for preventing acute organ rejection in various transplants.
• This study explores the initial use and outcomes of Basiliximab in lung transplantation.

Purpose of the Study:

• To evaluate the efficacy and safety of Basiliximab in lung transplant recipients.
• To assess the incidence of acute rejection and adverse events in patients receiving Basiliximab.

Main Methods:

• Basiliximab (20 mg doses on day 0 and 4) was administered to 16 lung transplant patients.
• Patients also received standard immunosuppression: cyclosporine, azathioprine, and steroids.
• Transplant indications included emphysema, idiopathic pulmonary fibrosis, silicosis, and cystic fibrosis.

Main Results:

• The incidence of acute rejection was 16.6% (2 patients).
• Common infections included cytomegalovirus (33.3%), bacterial (16.6%), and fungal (8.3%).
• No Basiliximab-related reactions, malignancies, or Bronchiolitis Obliterans Syndrome were observed within a year of follow-up.

Conclusions:

• Basiliximab demonstrated a reduction in acute organ rejection rates in lung transplant recipients.
• The drug exhibited a good safety profile, with low rates of serious infections and adverse events.